作者
Patrick W Serruys, John A Ormiston, Yoshinobu Onuma, Evelyn Regar, Nieves Gonzalo, Hector M Garcia-Garcia, Koen Nieman, Nico Bruining, Cécile Dorange, Karine Miquel-Hébert, Susan Veldhof, Mark Webster, Leif Thuesen, Dariusz Dudek
发表日期
2009/3/14
期刊
The Lancet
卷号
373
期号
9667
页码范围
897-910
出版商
Elsevier
简介
Background
Drug-eluting metallic coronary stents predispose to late stent thrombosis, prevent late lumen vessel enlargement, hinder surgical revascularisation, and impair imaging with multislice CT. We assessed the safety of the bioabsorbable everolimus-eluting stent (BVS).
Methods
30 patients with a single de-novo coronary artery lesion were followed up for 2 years clinically and with multiple imaging methods: multislice CT, angiography, intravascular ultrasound, derived morphology parameters (virtual histology, palpography, and echogenicity), and optical coherence tomography (OCT).
Findings
Clinical data were obtained from 29 of 30 patients. At 2 years, the device was safe with no cardiac deaths, ischaemia-driven target lesion revascularisations, or stent thromboses recorded, and only one myocardial infarction (non-Q wave). 18-month multislice CT (assessed in 25 patients) showed a mean diameter stenosis …
引用总数
学术搜索中的文章
PW Serruys, JA Ormiston, Y Onuma, E Regar… - The Lancet, 2009
